Teplizumab: promises and challenges of a recently approved monoclonal antibody for the prevention of type 1 diabetes or preservation of residual beta cell function,Expert Review of Clinical Immunology

当前位置： X-MOL 学术 › Expert Rev. Clin. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Teplizumab: promises and challenges of a recently approved monoclonal antibody for the prevention of type 1 diabetes or preservation of residual beta cell function
Expert Review of Clinical Immunology ( IF 4.4 ) Pub Date : 2024-01-21 , DOI: 10.1080/1744666x.2023.2281990
Nina Maria Fanaropoulou ₁ , Georgia C Tsatsani ₁ , Theocharis Koufakis ₂ , Kalliopi Kotsa ₃

Affiliation

Type 1 diabetes (T1D) is a chronic autoimmune endocrinopathy with increasing incidence that results in the depletion of pancreatic beta cells and exogenous insulin dependence. Despite technological...

中文翻译：